We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+8.29%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$329M
AUM Growth
+$77M
(+31%)
Cap. Flow
+$63.4M
Cap. Flow
% of AUM
19.29%
Top 10 Holdings %
Top 10 Hldgs %
77.94%
Holding
27
New
5
Increased
10
Reduced
4
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$18.2M |
| 2 |
Pacira BioSciences
PCRX
|
+$12.9M |
| 3 |
Zimmer Biomet
ZBH
|
+$10.9M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
+$10.5M |
| 5 |
Haemonetics
HAE
|
+$9.84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVRO
NEVRO CORP.
NVRO
|
+$6.85M |
| 2 |
Lantheus
LNTH
|
+$5.59M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$5.33M |
| 4 |
Alkermes
ALKS
|
+$5.11M |
| 5 |
Service Corp International
SCI
|
+$4.82M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.73% |
| 2 | Industrials | 6.8% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDRX
1
DELISTED
Veradigm Inc. Common Stock
MDRX
| $45.7M | 13.9% |
3,925,000
+375,000
| +11% | +$3.81M |
|
2
Medtronic
MDT
$107B
| $41.2M | 12.52% |
420,000
+70,000
| +20% | +$6.39M |
|
|
3
Bio-Rad Laboratories Class A
BIO
$8.42B
| $30.9M | 9.4% |
100,000
+35,000
| +54% | +$10.5M |
|
|
4
Pacira BioSciences
PCRX
$1.02B
| $27M | 8.22% |
625,000
+305,000
| +95% | +$12.9M |
|
|
SRCL
5
DELISTED
Stericycle Inc
SRCL
| $22.4M | 6.8% |
475,000
-35,000
| -7% | -$1.78M |
|
6
AtriCure
ATRC
$1.77B
| $21.2M | 6.44% |
675,000
+250,000
| +59% | +$7.3M |
|
|
7
Lantheus
LNTH
$6.82B
| $20.1M | 6.11% |
730,000
-220,000
| -23% | -$5.59M |
|
|
8
Quest Diagnostics
DGX
$25.1B
| $19.4M | 5.89% |
+188,900
| New | +$18.2M |
|
|
PTLA
9
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $14.4M | 4.38% |
555,000
-170,000
| -23% | -$5.33M |
|
10
Rigel Pharmaceuticals
RIGL
$680M
| $14M | 4.26% |
547,500
+17,500
| +3% | +$395K |
|
|
HOLX
11
DELISTED
Hologic
HOLX
| $13M | 3.96% |
275,000
+50,000
| +22% | +$2.31M |
|
|
12
Haemonetics
HAE
$3.58B
| $12.1M | 3.67% |
+100,000
| New | +$9.84M |
|
|
13
Zimmer Biomet
ZBH
$17.7B
| $10.9M | 3.3% |
+92,700
| New | +$10.9M |
|
14
NovoCure
NVCR
$2.04B
| $9.64M | 2.93% |
+150,000
| New | +$7.6M |
|
|
CMD
15
DELISTED
Cantel Medical Corporation
CMD
| $9.11M | 2.77% |
115,000
+85,000
| +283% | +$5.98M |
|
|
CORV
16
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $7.44M | 2.26% |
3,350,000
+950,000
| +40% | +$2.43M |
|
|
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $3.72M | 1.13% |
3,000,000
| – | – |
|
|
STRM
18
DELISTED
Streamline Health Solutions
STRM
| $3.28M | 1% |
140,000
+10,000
| +8% | +$193K |
|
|
NVRO
19
DELISTED
NEVRO CORP.
NVRO
| $3.15M | 0.96% |
50,000
-110,000
| -69% | -$6.85M |
|
20
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $264K | 0.08% |
4,000
| – | – |
|
21
PUT
Amgen
AMGN
$203B
| $11K | ﹤0.01% |
+250
| New | +$44.8K |
|
|
22
Alkermes
ALKS
$8.82B
| – | – |
-140,000
| Closed | -$5.11M |
|
|
HIND
23
Vyome Holdings
HIND
$14.5M
| – | – |
0
| – | -$2.94M |
|
|
24
Service Corp International
SCI
$11.4B
| – | – |
-120,000
| Closed | -$4.82M |
|
25
Thermo Fisher Scientific
TMO
$211B
| – | – |
-10,000
| Closed | -$2.74M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2019 Portfolio in Review
As of Q2 2019, Tamarack Advisers held 27 positions worth $329M, up 31% from $252M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Tamarack Advisers deployed $63.4M of net new capital in Q2 2019, opening 5 new positions and adding to 10 existing holdings. Its largest new stake was Quest Diagnostics: 188,900 shares worth $19.4M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 77% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was NEVRO CORP., an estimated $6.85M trimmed.
- Tamarack Advisers's largest Q2 2019 buy was Quest Diagnostics: 188,900 shares worth $19.4M.
- Tamarack Advisers added most to Pacira BioSciences in Q2 2019, an estimated $12.9M increase.
- Tamarack Advisers's biggest Q2 2019 reduction was NEVRO CORP., cutting an estimated $6.85M.
- Tamarack Advisers fully exited Alkermes in Q2 2019, selling an estimated $5.11M.
- Tamarack Advisers's ten largest holdings make up 78% of its $329M portfolio in Q2 2019.
- Tamarack Advisers opened 5 new positions and closed 5 in Q2 2019.
- Tamarack Advisers's portfolio value rose 31% quarter-over-quarter to $329M.
Based on Tamarack Advisers's 13F filing for Q2 2019, filed 12 Aug 2019.